Category: BUHLMANN Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to

BÜHLMANN GanglioCombi™ MAG ELISA Utilized in Guillain-Barré Syndrome (GBS) and Zika Virus Study

The BÜHLMANN GanglioCombi™ MAG ELISA was recently utilized in a case-control study in French Polynesia focusing on individuals diagnosed with Guillain-Barré Syndrome (GBS). See publication below: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Learn More BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures in

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Category: BUHLMANN Citations

Other BÜHLMANN Fecal Calprotectin Assays Citations

BÜHLMANN GanglioCombi™ MAG ELISA Utilized in Guillain-Barré Syndrome (GBS) and Zika Virus Study

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US